Olfactive Biosolutions Files Patent to Repurpose Food Molecules for Weight Loss
Similar Mechanism of Action (MOA) as Semaglutide and Tirzepatide, Proprietary Blends of Food Ingredients to Combat Obesity, Improve Health
Protenx™ Line of Food Ingredient Formulations includes dual GLP-1 / GIP receptor agonists
Mountain View, CA. Jan. 16, 2024---- Olfactive Biosolutions, a leader in ectopic and chemosensory receptor technology, recently filed a U.S. patent for Protenx, a proprietary line of breakthrough food ingredient formulations. The Protenx weight loss formula for example activates the same dual GLP-1 and GIP pathways as tirzepatide, to facilitate weight loss and blood sugar regulation. Protenx weight loss formula integrates into consumer products, bringing to them the potential of achieving benefits consistent with current weight loss prescription-only pharmaceuticals.
Protenx accomplishes this while avoiding harmful side effects and high cost. Blended into everyday food and drinks such as coffee, Protenx does not require any changes in consumer routines. With its proprietary blend of food ingredients, Protenx targets olfactory and taste receptors in the gut (ectopic receptors) and elsewhere throughout the body to induce similar effects as pharmaceutical agents, to:
• Induce weight loss
• Lower blood sugar
• Slow gastric emptying
• Lower blood pressure
• Increase bronchodilation
• Promote muscle gain
• Increase bone remodeling
• Reduce inflammation, and
• Induce the release of neurotransmitters such as serotonin, GABA and dopamine.
Olfactive BioSolutions can then use its knowledge of olfactory and taste receptors to adjust the hedonics, to ensure the products maintain the same flavor and aroma.
Protenx is slated for general availability in Q4 2024. Protenx proprietary formulations may be added to new or existing consumer products. The Protenx patent also allows for administration including but not limited to topically, sublingual lozenges, inhaled or administered in multiple other ways.
“We are excited to have filed patents for Protenx. With related products currently in development, we will offer consumers a comprehensive platform that can safely control their weight, blood sugar, blood pressure and other conditions,” said Nils Lommerin, President and CEO of Olfactive Biosolutions.
Using the ectopic, olfactory and taste receptor genes along with selected genes for intracellular signaling, Olfactive Biosolutions has engineered mammalian biosensor cells to behave in a manner like the ectopic, olfactory and taste neuron cells in humans. Olfactive Biosolutions biosensor cells produce discreet, measurable luminescent signals when an engineered receptor on the cell’s surface binds to its complementary ingredient molecules.
Using multiple receptors in a multi-well disposable plate, an ingredient sample can be presented to numerous human ectopic, olfactory and taste receptors to determine which receptors are activated. Biochemical parameters such as EC50s (the amount of a chemical required to activate a receptor to 50 percent of its maximum activity) and the limit of detection (LOD) of the molecules present in the samples can be determined. This information allows a sample to be chemically characterized with great specificity and sensitivity.
“Protenx is the culmination of years of work and the efforts of many Olfactive Biosolutions dedicated scientists,” said Dr. William Harries, the company’s chief scientist
About Olfactive Biosolutions
Olfactive Biosolutions has developed world-leading receptor technology and expertise in both ectopic receptors in the gut, lungs, skin, heart, blood and elsewhere, and olfactory and taste receptors in the nose and tongue.
Its unique technology demonstrates how ectopic receptors often perform the same physiologic tasks as active pharmaceutical ingredients or APIs, and what ligands activate or inhibit them.
The same technology accurately measures the actual taste and smell of existing products, allowing the company to anchor the hedonics of a customer’s product, so it tastes and smells exactly like the original even after the addition of Protenx.
The Olfactive Biosolutions team has deep expertise in receptor protein science, artificial intelligence (AI) and the food & beverage industry. The company has several well-known biotechnology and AI advisors from academia and the corporate world.
To learn more, visit https://olfactive.bio or follow us on LinkedIn.
Investors contact:
Nils Lommerin
(949) 205-5776
Media contact:
Deb Stapleton
(650) 815-1239